Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

quantum physics

- PMLiVE

GSK signs up to apply AI to drug discovery

Will work with Exscientia on 10 small molecule targets

- PMLiVE

MSD probed by UK for blocking Remicade biosimilars

Pharma giant’s discount scheme for infliximab labelled ‘anti-competitive’

- PMLiVE

Keytruda is first FDA-approved drug for molecular indication

Indicates a significant development in the shift towards personalised medicine

- PMLiVE

Merck says Afferent’s chronic cough drug clears mid-stage trial

MK-7264 reduces coughs per hour by 37%

- PMLiVE

Merck takes on Roche with first-line bladder OK for Keytruda

FDA awards accelerated approval for mUC patients

- PMLiVE

Merck gains ground in lung cancer with first-line combo approval

Keytruda wins FDA backing for all first-line NSCLC patients

- PMLiVE

FDA won’t add outcomes data to Januvia label

Merck & Co’s application rejected despite TECOS outcomes data

- PMLiVE

Keytruda and Opdivo backed for new uses in Europe

CHMP recommendations also include Trumenba, Dinutuximab beta and Refixia

Bristol-Myers Squibb (BMS) building

BMS replaces R&D head in wake of Opdivo setbacks

As Merck & Co’s Keytruda gains the lion’s share of the market

- PMLiVE

Merck & Co and Pfizer take aim at diabetes with trio of new drugs

File ertugliflozin-based products with EU and US regulators

- PMLiVE

Merck BACE inhibitor adds to litany of Alzheimer’s trial failures

Interim data shows “virtually no chance” of clinical success for verubecestat

- PMLiVE

Keytruda filed for first- and second-line bladder cancer

Merck & Co hopes to gain advantage over Opdivo and Tecentriq with first-line setting

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links